Anti-Fn14 TNFRSF12A Antibody

TWEAK is a TNF family member produced by IFN-gamma-stimulated monocytes and induces multiple cell death pathways including caspase-dependent apoptosis and cathepsin B-dependent necrosis. These pathways are mediated by the binding of TWEAK by fibroblast growth factor 14 (Fn14), a member of the TNF receptor superfamily. Yeast two-hybrid experiments have shown that FN14 will bind to the TNFR-associated factors TRAF1, TRAF2, TRAF3, and TRAF5, suggesting that the signaling pathway induced by TWEAK may be mediated by one or more of these adaptor molecules. Fn14 is induced during liver regeneration and is highly expressed in hepatocellular carcinomas. In addition, TWEAK induces liver progenitor cell proliferation, suggesting Fn14 may play a role in hepatocyte growth control and liver neoplasia.

FN14, CD266, TWEAKR, FN14, Tumor necrosis factor receptor superfamily member 12A, Fibroblast growth factor-inducible immediate-early response protein 14, FGF-inducible 14

Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins.

Fn14 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.